Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3273-3278

  Weiss, Thomas Werner ^a,b,c   Simak, Rainer ^d   Kaun, Christoph ^b,e   Rega, Gersina ^b   Pflüger, Heinz ^d   Maurer, Gerald ^b   Huber, Kurt ^a   Wojta, Johann ^b,e  

^a WILHELMINEN HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d GENERAL HOSPITAL LINZ   (Austria)

^e Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

Author keywords

Interleukin 6; Oncostatin M; Prostate cancer; u PA; VEGF

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA; ONCOSTATIN M; UROKINASE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

AGED; CELL LINE, TUMOR; CYTOKINE RECEPTOR GP130; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; LIGANDS; MALE; NEOPLASM METASTASIS; ONCOSTATIN M; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RNA, MESSENGER; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80054754783     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 49(1): 8-31, 31, 1999.
2. Culig Z, Steiner H, Bartsch G and Hobisch A: Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95(3): 497-505, 2005. (Pubitemid 41420180)
3. Okamoto M, Lee C and Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57(1): 141-146, 1997. (Pubitemid 27020343)
4. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travail S and D'Alessandro N: Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 85(1): 134-144, 1999. (Pubitemid 29031367)
5. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT and Thompson TC: Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161(1): 182-187, 1999. (Pubitemid 29422316)
6. Mori S, Murakami-Mori K and Bonavida B: Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. Anticancer Res 19(2A): 1011-1015, 1999. (Pubitemid 29257530)
7. Godoy-Tundidor S, Cavarretta IT, Fuchs D, Fiechtl M, Steiner H, Friedbichler K, Bartsch G, Hobisch A and Culig Z: Interleukin-6 and oncostatin M Stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Prostate 64(2): 209-216, 2005. (Pubitemid 40791771)
8. Li WQ, Dehnade F and Zafarullah M: Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 166(5): 3491-3498, 2001. (Pubitemid 33117353)
9. Vasse M, Pourtau J, Trochon V, Muraine M, Vannier JP, Lu H, Soria J and Soria C: Oncostatin M induces angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol 19(8): 1835-1842, 1999. (Pubitemid 29379912)
10. Sidenius N and Blasi F: The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22(2-3): 205-222, 2003. (Pubitemid 36561058)
11. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V and Garbisa S: Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41(11 Pt 1): 4629-4636, 1981. (Pubitemid 12201384)
12. Murphy G, Atkinson S, Ward R, Gavrilovic J and Reynolds JJ: The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad Sci 667: 1-12, 1992. (Pubitemid 23061556)
13. Gavrilov D, Kenzior O, Evans M, Calaluce R and Folk WR: Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. Eur J Cancer 37(8): 1033-1040, 2001. (Pubitemid 32397690)
14. Van Veldhuizen PJ, Sadasivan R, Cherian R and Wyatt A: Urokinase-type plasminogen activator expression in human prostate carcinomas. Am J Med Sci 312(1): 8-11, 1996. (Pubitemid 26238890)
15. Kirchheimer JC, Pfluger H, Ritschl P, Hienert G and Binder BR: Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Invasion Metastasis 5(6): 344-355, 1985. (Pubitemid 16219665)
16. McCabe NP, Angwafo FF, 3rd, Zaher A, Selman SH, Kouinche A and Jankun J: Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol Rep 7(4): 879-882, 2000.
17. Miyake H, Hara I, Yamanaka K, Arakawa S and Kamidono S: Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol 14(5): 535-541, 1999.
18. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S and Kamidono S: Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39(2): 123-129, 1999. (Pubitemid 29194284)
19. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82(1): 4-6, 1990.
20. Folkman J and Shing Y: Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 313: 355-364, 1992.
21. Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143(2): 401-409, 1993. (Pubitemid 24058195)
22. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D and Freeman MR: Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54(3): 523-527, 1999. (Pubitemid 29407032)
23. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP and Kreutzer DL: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157(6): 2329-2333, 1997. (Pubitemid 27208716)
24. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC and Kreutzer DL: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54(3): 567-572, 1999. (Pubitemid 29407042)
25. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ and Kantoff PW: Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7(7): 1932-1936, 2001. (Pubitemid 32994827)
26. Hahn D, Simak R, Steiner GE, Handisurya A, Susani M and Marberger M: Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J Urol 164(2): 506-510, 2000. (Pubitemid 30481975)
27. Jackson MW, Bentel JM and Tilley WD: Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157(6): 2323-2328, 1997. (Pubitemid 27208715)
28. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ and Tilley WD: A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 62(3): 854-859, 2002. (Pubitemid 34126964)
29. Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Bicknell R and Harris AL: Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int 85(3): 276-280, 2000. (Pubitemid 30088518)
30. Chevalier S, Defoy I, Lacoste J, Hamel L, Guy L, Begin LR and Aprikian AG: Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis. Mol Cell Endocrinol 189(1-2): 169-179, 2002. (Pubitemid 34229174)
31. Arndt A, Murphy P and Hart DA: Human HuH-7 hepatoma cells express urokinase and plasminogen activator inhibitor-1: identification, characterization and regulation by inflammatory mediators. Biochim Biophys Acta 1138(2): 149-156, 1992.
32. Rega G, Kaun C, Demyanets S, Pfaffenberger S, Rychli K, Hohensinner PJ, Kastl SP, Speidl WS, Weiss TW, Breuss JM, Furnkranz A, Uhrin P, Zaujec J, Zilberfarb V, Frey M, Roehle R, Maurer G, Huber K and Wojta J: Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo. Arterioscler Thromb Vasc Biol 27(7): 1587-1595, 2007. (Pubitemid 46986114)
33. Rega G, Kaun C, Weiss TW, Demyanets S, Zorn G, Kastl SP, Steiner S, Seidinger D, Kopp CW, Frey M, Roehle R, Maurer G, Huber K and Wojta J: Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 111(15): 1938-1945, 2005. (Pubitemid 40570213)
34. Steiner H, Berger AP, Godoy-Tundidor S, Bjartell A, Lilja H, Bartsch G, Hobisch A and Culig Z: An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Eur J Cancer 40(7): 1066-1072, 2004. (Pubitemid 38496265)